Back to Journals » Neuropsychiatric Disease and Treatment » Volume 13

Successful treatment for psychomotor agitation in neuromyelitis optica spectrum disorder with trazodone–risperidone combination: a case report

Authors Narita Z, Takano H, Sumiyoshi T

Received 16 January 2017

Accepted for publication 17 February 2017

Published 13 March 2017 Volume 2017:13 Pages 775—777

DOI https://doi.org/10.2147/NDT.S132516

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Roumen Kirov

Peer reviewer comments 3

Editor who approved publication: Dr Taro Kishi


Zui Narita,1 Harumasa Takano,1 Tomiki Sumiyoshi2

1Department of Psychiatry, National Center Hospital, 2Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan

Abstract: Neuromyelitis optica (NMO) is a relapsing disease that typically affects the spinal cord and optic nerves. So far, a few studies have reported pharmacologic treatment for psychiatric symptoms in patients with NMO spectrum disorder (NMOSD). However, no literature has described psychomotor agitation associated with the disease and its treatment. We report an 84-year-old woman with NMOSD whose psychomotor agitation was effectively treated with a combination of trazodone and risperidone. Our observation suggests the ability of augmentation of antipsychotic drugs with antidepressants to ameliorate psychotic symptoms associated with NMOSD.

Keywords: neuromyelitis optica, multiple sclerosis, psychomotor agitation, trazodone, risperidone

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]